Gamma-aminobutyric acid / IL6 Cancer Research Results

GABA, Gamma-aminobutyric acid: Click to Expand ⟱
Features:
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, and its dysregulation has been implicated in Alzheimer’s disease (AD).
-Altered GABA levels: Some studies report reduced GABA levels in the brain of AD patients, while others show compensatory increases in certain brain areas.
Enhancing GABAergic signaling is being explored to:
-Reduce neuronal hyperexcitability.
-Alleviate agitation, anxiety, and seizure-like activity in AD.
-Improve memory and cognition in early disease stages.

-dietary sources of GABA. They include broccoli and other cruciferous vegetables, certain peas and beans, and oat, wheat, barley, rice, tomatoes, sweet potatoes, and spinach
-GABA intake from dietary sources like tomatoes and fermented foods can be considerable
-GABA, is synthesized from glutamate

Cancer evidence status: No clinical evidence supports oral GABA supplements or GABA-enriched foods as cancer treatments. Experimental cancer studies primarily examine endogenous tumor GABA, GABA receptors, GABA-shunt metabolism, or direct exposure of cultured cells to GABA. Reported effects are bidirectional and highly tumor-dependent, including both growth inhibition and promotion of proliferation, invasion, metabolic adaptation, and immune suppression. These findings support GABAergic signaling as a mechanistic cancer target but do not establish supplemental GABA as an anticancer intervention.



Alzheimer’s disease relevance: GABAergic dysfunction is significantly involved in Alzheimer’s disease, but it cannot be represented simply as a uniform GABA deficiency. Loss or dysfunction of inhibitory interneurons can reduce network inhibition, increase hippocampal hyperexcitability, disrupt gamma oscillations, and increase seizure susceptibility. Conversely, reactive astrocytes can produce excessive tonic GABA in affected regions, suppressing synaptic plasticity and memory circuits. The therapeutically relevant objective is restoration of spatially and receptor-subtype-specific excitation–inhibition balance rather than generalized enhancement of GABA signaling. Oral GABA is not an established Alzheimer’s disease treatment, has limited blood–brain barrier penetration, and lacks adequate randomized evidence for cognitive or disease-modifying benefit.

Primary mechanisms (ranked):

  1. Restoration or disruption of neuronal excitation–inhibition balance through GABAA and GABAB receptors.
  2. Regulation of hippocampal and cortical hyperexcitability, network oscillations, and seizure susceptibility.
  3. Reactive-astrocyte GABA production and excessive tonic inhibition of memory-related neurons.
  4. Modulation of synaptic plasticity, long-term potentiation, learning, and memory according to receptor subtype and anatomical region.
  5. Indirect gut–brain, autonomic, endocrine, sleep, and stress effects from peripheral or microbiota-derived GABA.

Bioavailability / PK relevance: Endogenous brain GABA is locally synthesized and tightly compartmentalized. Supplemental GABA produces peripheral exposure but appears to cross an intact blood–brain barrier poorly. Increased oral intake therefore cannot be assumed to normalize cerebral GABA concentrations or selectively reach dysfunctional Alzheimer’s disease circuits.

In-vitro vs systemic exposure relevance: Cell and animal studies using direct intracerebral delivery, receptor-selective drugs, genetic manipulation, or millimolar GABA exposure do not directly model ordinary dietary supplementation. Effects of selective GABA receptor modulators cannot be attributed automatically to oral GABA.

Clinical evidence status: Mechanistic and animal evidence supports GABAergic pathways as Alzheimer’s disease targets, but direct oral GABA evidence is inadequate. Historical studies of GABAergic drugs and more recent receptor-selective approaches have not established GABA supplementation as a cognitive or disease-modifying therapy. Clinical status remains preclinical to exploratory human evidence.

Alzheimer’s Disease Mechanistic Profile

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Excitation–inhibition balance GABAergic inhibition ↓ in dysfunctional interneuron networks; tonic inhibition ↑ in selected regions P–G Controls neuronal stability and information processing Alzheimer’s disease can contain simultaneous regional hypo-inhibition and excessive tonic inhibition. Global GABA enhancement is therefore unlikely to be uniformly beneficial.
2 Network hyperexcitability Hyperexcitability ↑ when interneuron function or phasic inhibition is impaired P–G Promotes abnormal firing, impaired coding, and seizure susceptibility Restoring appropriately timed inhibition may improve network function, but excessive suppression can impair cognition.
3 Reactive astrocyte GABA Astrocytic GABA synthesis and tonic release ↑ (model-dependent) G Suppresses hippocampal neuronal activity and memory circuits This mechanism argues against treating Alzheimer’s disease as a simple state of insufficient GABA.
4 Synaptic plasticity and memory Long-term potentiation ↓ with excessive tonic inhibition; may improve when pathological inhibition is normalized R–G Modulates learning, memory formation, and retrieval GABAA receptor subtypes have distinct cognitive effects; receptor-selective modulators may differ substantially from GABA supplementation.
5 Gamma oscillations and interneuron synchrony Oscillatory synchrony ↓ with interneuron dysfunction P–G Impairs coordinated cortical and hippocampal processing Parvalbumin interneurons and precisely timed GABA release are more relevant than bulk tissue GABA concentration.
6 Clinical Translation Constraint Brain delivery uncertain; receptor and regional selectivity absent G Limits therapeutic interpretation of oral supplementation No adequate evidence demonstrates that oral GABA improves Alzheimer’s disease cognition, pathology, or progression.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


Scientific Papers found: Click to Expand⟱
7080- GABA,    The Effect of Oral GABA on the Nervous System: Potential for Therapeutic Intervention
- Review, AD, NA
*BBB↝, *cognitive↑, *Dose↝, *toxicity↓, *Stress↓, *Inflam↓, *iNOS↓, *COX2↓, *IL6↓, *IL1β↓, *TNF-α↓, *Sleep↑, *Pain↓, *neuroP↑, *eff↑, *Ach↑, *AST↓, *ALAT↓, *BP↓, *other↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

Stress↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,   other↝, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   neuroP↑, 1,   Pain↓, 1,   Sleep↑, 1,   toxicity↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:342  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page